Cardiovascular toxicities from systemic breast cancer therapy

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Cardiovascular toxicity is a significant concern for patients undergoing breast cancer therapy.
• Both conventional chemotherapy (e.g., anthracyclines) and targeted therapies (e.g., trastuzumab) can lead to cardiac dysfunction.
• Cardiac toxicity can manifest as Type I (dose-dependent, irreversible) or Type II (non-dose-dependent, reversible) dysfunction.

Purpose of the Study:

• To review the cardiovascular effects of systemic breast cancer treatments.
• To explore the mechanisms underlying treatment-induced cardiotoxicity.
• To discuss the role of biomarkers and prevention strategies for cardiovascular complications.

Main Methods:

• Literature review of studies on breast cancer therapy and cardiovascular effects.
• Analysis of mechanisms of cardiac toxicity for different drug classes.
• Evaluation of current biomarkers and preventive measures.

Main Results:

• Systemic breast cancer treatments pose risks for short- and long-term cardiac dysfunction.
• Anthracyclines and trastuzumab are associated with distinct patterns of cardiotoxicity.
• Understanding toxicity mechanisms is crucial for risk stratification and management.

Conclusions:

• Cardiovascular complications are a critical aspect of breast cancer treatment management.
• Further research into predictive biomarkers and cardioprotective strategies is warranted.
• Multidisciplinary approaches are essential to minimize cardiac risks in breast cancer survivors.